The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 09, 2003

Filed:

Aug. 21, 2000
Applicant:
Inventors:

Robert H. Christenson, Joppa, MD (US);

Show-Hong Duh, Ellicott City, MD (US);

Robin T. Vollmer, Durham, NC (US);

E. Magnus Ohman, Durham, NC (US);

Trevor D. Thompson, Lilburn, GA (US);

L. Kristin Newby, Durham, NC (US);

Robert M. Califf, Durham, NC (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 3/348 ; C12Q 1/00 ; C12Q 1/48 ; G06G 7/48 ;
U.S. Cl.
CPC ...
G01N 3/348 ; C12Q 1/00 ; C12Q 1/48 ; G06G 7/48 ;
Abstract

A method for predicting the clinical outcome for a patient after the patient has received therapy for an acute coronary syndrome such as myocardial infarction comprises: (a) optionally, but preferably, detecting a first variable comprising a serum creatine kinase-MB release curve area in the patient after initiation of said therapy; (b) detecting a second variable comprising a serum creatine kinase-MB release curve maxima in the patient after initiation of said therapy; then (c) optionally, but preferably, detecting a third variable comprising the slope of the descending portion of the serum creatine kinase-MB release curve after initiation of said therapy (wherein a steep slope for said descending portion is a more favorable indicator of clinical outcome than a shallow slope); and (d) generating a prediction of clinical outcome for said patient from the variables collected above. The method is useful in conjunction with established therapies such as thrombolytic therapy, and is particularly useful as a surrogate end point in clinical trials of new potential therapies.


Find Patent Forward Citations

Loading…